EMA Recommends Granting a Marketing Authorisation for Aumolertinib By Ogkologos - January 8, 2026 379 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with EGFR-mutated NSCLC Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Five Questions With…Sharon. May 12, 2022 Longest Follow-Up for ICI Plus TKI Favours Treatment with Avelumab Plus... February 11, 2025 Neoadjuvant Nivolumab/Relatlimab Induces High Rates of Pathologic Responses in Patients with... November 22, 2024 Husband Moved To Tears After Opening Christmas Gift From Wife December 31, 2021 Load more HOT NEWS Coming Full Circle on Cancer and Extrachromosomal DNA Researchers Find a Way to Prevent Cancer Cells from Taking in... ESMO Calls for Cancer Care Safeguards in the EU’s Health Crisis... Adjuvant Pembrolizumab Continues to Demonstrate a Clinically Meaningful DMFS Benefit in...
